Kare Family Private Trust has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kare Family Private Trust (KFPT), a promoter group entity of Indoco Remedies, acquired 55,34,874 equity shares (6.00% of share capital) directly from promoter Aruna Suresh Kare on 26th December 2025 at nil consideration. KFPT also picked up a 40% stake in Shanteri Investment Pvt Ltd (SIPL) and a 20.16% stake in SPA Holdings Pvt Ltd (SHPL), which together hold 37.07% of Indoco Remedies. The transfer is an off-market, inter-se family arrangement for succession planning and to streamline family assets. As a result, KFPT's direct holding in Indoco Remedies rose from 8.20% to 14.20%, while Aruna Suresh Kare's holding went to zero. No open offer is triggered because the exemption under Regulation 10(1)(a)(i) applies to transfers among immediate relatives.
This is an internal promoter family restructuring with no change in the ultimate promoter group's control over Indoco Remedies and no cash transaction, so it is unlikely to have a material impact on the share price. Shareholders should note that the legal ownership within the promoter family has been consolidated under the Kare Family Private Trust, which may affect how future promoter actions are reported.